BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

534 related articles for article (PubMed ID: 23287459)

  • 1. Neutrophils as effector cells for antibody-based immunotherapy of cancer.
    van Egmond M; Bakema JE
    Semin Cancer Biol; 2013 Jun; 23(3):190-9. PubMed ID: 23287459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myeloid cells as effector cells for monoclonal antibody therapy of cancer.
    Braster R; O'Toole T; van Egmond M
    Methods; 2014 Jan; 65(1):28-37. PubMed ID: 23811299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutrophils in antibody-based immunotherapy of cancer.
    van Egmond M
    Expert Opin Biol Ther; 2008 Jan; 8(1):83-94. PubMed ID: 18081538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal antibody-mediated killing of tumour cells by neutrophils.
    Heemskerk N; van Egmond M
    Eur J Clin Invest; 2018 Nov; 48 Suppl 2(Suppl Suppl 2):e12962. PubMed ID: 29855035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fc receptor-dependent mechanisms of monoclonal antibody therapy of cancer.
    Bakema JE; van Egmond M
    Curr Top Microbiol Immunol; 2014; 382():373-92. PubMed ID: 25116109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy.
    Houot R; Kohrt HE; Marabelle A; Levy R
    Trends Immunol; 2011 Nov; 32(11):510-6. PubMed ID: 21907000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement as effector system in cancer immunotherapy.
    Macor P; Tedesco F
    Immunol Lett; 2007 Jul; 111(1):6-13. PubMed ID: 17572509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human anti-murine immunoglobulin responses and immune functions in cancer patients receiving murine monoclonal antibody therapy.
    Blottière HM; Steplewski Z; Herlyn D; Douillard JY
    Hum Antibodies Hybridomas; 1991 Jan; 2(1):16-25. PubMed ID: 1908336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct functions of surface receptors in the induction of neutrophil-mediated cytotoxicity.
    Cordier G; Samarut C; Revillard JP
    Ann Immunol (Paris); 1981; 132D(1):3-14. PubMed ID: 7347555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoglobulin A: magic bullet or Trojan horse?
    Heineke MH; van Egmond M
    Eur J Clin Invest; 2017 Feb; 47(2):184-192. PubMed ID: 28024097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lysis of human tumor cell lines by canine complement plus monoclonal antiganglioside antibodies or natural canine xenoantibodies.
    Helfand SC; Hank JA; Gan J; Sondel PM
    Cell Immunol; 1996 Jan; 167(1):99-107. PubMed ID: 8548851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimaeric Lym-1 monoclonal antibody-mediated cytolysis by neutrophils from G-CSF-treated patients: stimulation by GM-CSF and role of Fc gamma -receptors.
    Ottonello L; Epstein AL; Mancini M; Tortolina G; Dapino P; Dallegri F
    Br J Cancer; 2001 Aug; 85(3):463-9. PubMed ID: 11487281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of complement by monoclonal antibodies that target cell-associated β₂-microglobulin: implications for cancer immunotherapy.
    Pokrass MJ; Liu MF; Lindorfer MA; Taylor RP
    Mol Immunol; 2013 Dec; 56(4):549-60. PubMed ID: 23911412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effector characteristics of the IgG3 murine monoclonal antibody 113F1.
    Weiner LM; Zarou CM; O'Brien J; Ring D
    J Biol Response Mod; 1989 Jun; 8(3):227-37. PubMed ID: 2787391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Monoclonal antibodies: therapeutic possibilities and limitations].
    Tax WJ; Capel PJ; Koene RA
    Tijdschr Kindergeneeskd; 1987 Feb; 55(1):1-9. PubMed ID: 3551184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced cytotoxicity against colon carcinoma by combinations of noncompeting monoclonal antibodies to the 17-1A antigen.
    Fogler WE; Klinger MR; Abraham KG; Gottlinger HG; Riethmuller G; Daddona PE
    Cancer Res; 1988 Nov; 48(22):6303-8. PubMed ID: 2460221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting of cytotoxic cells against tumors with heterocrosslinked, bispecific antibodies.
    Segal DM; Qian JH; Garrido MA; Perez P; Winkler DF; Wunderlich JR; Snider DP; Valdayo MJ; Titus JA
    Princess Takamatsu Symp; 1988; 19():323-31. PubMed ID: 3269363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutrophil--mediated cytotoxicity against tumour cells: state of art.
    Dallegri F; Ottonello L
    Arch Immunol Ther Exp (Warsz); 1992; 40(1):39-42. PubMed ID: 1362490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plant-derived anti-Lewis Y mAb exhibits biological activities for efficient immunotherapy against human cancer cells.
    Brodzik R; Glogowska M; Bandurska K; Okulicz M; Deka D; Ko K; van der Linden J; Leusen JH; Pogrebnyak N; Golovkin M; Steplewski Z; Koprowski H
    Proc Natl Acad Sci U S A; 2006 Jun; 103(23):8804-9. PubMed ID: 16720700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.